** Shares of biotech firm Immunic IMUX.O rise 5% to $1.08 premarket

** Co says it appointed Jon Congleton to its board; he helped launch Teva’s multiple sclerosis drug Copaxone in the United States

** Congleton has also served as CEO of Mineralys Therapeutics, Impel NeuroPharma and Nivalis Therapeutics,

** Adds it is developing vidofludimus calcium, an oral experimental drug for relapsing multiple sclerosis, a form of the disease with recurring flare‑ups

** Co says late‑stage study readouts for the drug are expected by the end of 2026

** Multiple sclerosis is a disease in which the immune system attacks nerves, leading to problems with movement and vision

** Shares fell ~47% in 2025